33 results on '"Schönland, Stefan"'
Search Results
2. Comparison of IGLV2‐14 light chain sequences of patients with AL amyloidosis or multiple myeloma.
3. Quality of life and symptoms among patients with relapsed/refractory AL amyloidosis treated with ixazomib‐dexamethasone versus physician's choice.
4. Statin‐based endothelial prophylaxis and outcome after allogeneic stem cell transplantation.
5. Concurrent light chain amyloidosis and proximal tubulopathy: Insights into different aggregation behavior—A case report.
6. Health‐related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the ANDROMEDA study.
7. Submyeloablative total body irradiation‐based conditioning and allogeneic stem cell transplantation in high‐risk myeloma with early progression after up‐front autologous transplantation.
8. Lenalidomide and dexamethasone in relapsed/refractory immunoglobulin light chain (AL) amyloidosis: results from a large cohort of patients with long follow‐up.
9. Impact of time to diagnosis on Mayo stages, treatment outcome, and survival in patients with AL amyloidosis and cardiac involvement.
10. Daratumumab, lenalidomide, and dexamethasone in systemic light‐chain amyloidosis: High efficacy, relevant toxicity and main adverse effect of gain 1q21.
11. Ruxolitinib is effective in the treatment of a patient with refractory T‐ALL.
12. P899: HOVON 104; LONG TERM FOLLOW‐UP OF AUTOLOGOUS STEM CELL TRANSPLANTATION AFTER BORTEZOMIB INDUCTION THERAPY IN PATIENTS WITH NEWLY DIAGNOSED AL AMYLOIDOSIS.
13. P352: PROPHYLACTIC AND PREEMPTIVE USE OF DLI COMPARE FAVOURABLY TO THEIR THERAPEUTIC USE IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) – RESULTS OF A MULTICENTRE RETROSPECTIVE STUDY.
14. S198: EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK.
15. Localized immunoglobulin light chain amyloidosis: Novel insights including prognostic factors for local progression.
16. Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID‐19 pandemic.
17. Treosulfan conditioning for allogeneic transplantation in multiple myeloma – improved overall survival in first line haematopoietic stem cell transplantation – a large retrospective study by the Chronic Malignancies Working Party of the EBMT.
18. Magnetization transfer ratio quantifies polyneuropathy in hereditary transthyretin amyloidosis.
19. Conditioning‐based outcomes after allogeneic transplantation for myeloma following a prior autologous transplant (1991‐2012) on behalf of EBMT CMWP.
20. Quantification of number of CD38 sites on bone marrow plasma cells in patients with light chain amyloidosis and smoldering multiple myeloma.
21. CD7 is expressed on a subset of normal CD34‐positive myeloid precursors.
22. Efficacy and tolerability of the histone deacetylase inhibitor panobinostat in clinical practice.
23. Common Fibril Structures Imply Systemically Conserved Protein Misfolding Pathways In Vivo.
24. Potential therapeutic targets in plasma cell disorders: A flow cytometry study.
25. Reduced 8‐Gray Compared to Standard 12‐Gray Total Body Irradiation for Allogeneic Transplantation in First Remission Acute Lymphoblastic Leukemia: A Study of the Acute Leukemia Working Party of the EBMT.
26. Flow cytometry-based characterization of underlying clonal B and plasma cells in patients with light chain amyloidosis.
27. Polymorphism of Amyloid Fibrils In Vivo.
28. Polymorphismus von Amyloidfibrillen in vivo.
29. Seroconversion Rates After the Second COVID-19 Vaccination in Patients With Systemic Light Chain (AL) amyloidosis.
30. Modified body mass index and time interval between diagnosis and operation affect survival after liver transplantation for hereditary amyloidosis: a single-center analysis.
31. Global characteristics and outcomes of autologous hematopoietic stem cell transplantation for newly diagnosed multiple myeloma: A study of the worldwide network for blood and marrow transplantation (WBMT).
32. Trends in autologous stem cell transplantation for newly diagnosed multiple myeloma: Changing demographics and outcomes in European Society for Blood and Marrow Transplantation centres from 1995 to 2019.
33. Centre characteristics and procedure-related factors have an impact on outcomes of allogeneic transplantation for patients with CLL: a retrospective analysis from the European Society for Blood and Marrow Transplantation (EBMT).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.